NCT04317066View on ClinicalTrials.gov

A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 26, 2020

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions
Lymphoma, B-Cell
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg by intravenous (IV) infusion, given on day 1 of each 3-week cycle.

Trial Locations (9)

466-8560

Nagoya University Hospital ( Site 0002), Nagoya

060-8648

Hokkaido University Hospital ( Site 0006), Sapporo

589-8511

Kindai University Hospital ( Site 0001), Sayama

190-0014

National Hospital Organization Disaster Medical Center ( Site 0007), Tachikawa

812-8582

Kyushu University Hospital ( Site 0008), Fukuoka

700-8558

Okayama University Hospital ( Site 0004), Okayama

104-0045

National Cancer Center Hospital ( Site 0005), Tokyo

113-8677

Tokyo Metropolitan Komagome Hospital ( Site 0009), Tokyo

990-9585

Yamagata University Hospital ( Site 0003), Yamagata

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT04317066 - A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33) | Biotech Hunter | Biotech Hunter